论文部分内容阅读
[目的]探讨恩替诺特对K562人慢性粒细胞白血病细胞株G_0/G_1细胞周期的影响.[方法]采用CCK-8试剂盒观察恩替诺特对体外培养的K562人慢性粒细胞白血病细胞生长抑制的影响,并利用流式细胞仪检测细胞周期.[结果]CCK-8试剂盒观察结果显示,与对照组比较,随着恩替诺特药物浓度的增加及作用时间的延长,K562细胞抑制率显著升高(P<0.05).流式细胞仪分析结果显示,恩替诺特可使K562细胞阻滞于G_0/G_1期,且阻滞细胞的数量与药物浓度呈正相关(P<0.05);恩替诺特作用48h时对细胞周期的阻滞作用最强.[结论]恩替诺特通过阻滞细胞周期于G_0/G_1期而抑制K562细胞增殖.
[Objective] To investigate the effect of enhencinol on the cell cycle of K562 human chronic myelogenous leukemia cell line G_0 / G_1. [Methods] CCK-8 kit was used to observe the effect of enhencinol on K562 human chronic myelogenous leukemia cells Cell cycle was detected by flow cytometry. [Results] The results of CCK-8 kit showed that compared with the control group, K562 cells increased with the increase of Entecate concentration and the prolongation of action time (P <0.05) .Flow cytometry analysis showed that entecavan could block K562 cells in G_0 / G_1 phase, and the number of arrested cells was positively correlated with drug concentration (P <0.05 ). Entebbe was the strongest inhibitor of cell cycle arrest at 48h. [Conclusion] Entecavir inhibits the proliferation of K562 cells by arresting the cell cycle at G_0 / G1 phase.